• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

匹那地尔对正常血压志愿者血流动力学效应的药效学模型

Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers.

作者信息

Girard P, Saumet J L, Dubois F, Boissel J P

机构信息

INSERM, Lyon, France.

出版信息

Eur J Clin Pharmacol. 1993;44(2):177-82. doi: 10.1007/BF00315477.

DOI:10.1007/BF00315477
PMID:8453963
Abstract

The concentration-effect relationships of pinacidil, a peripheral vasodilator, have been measured in 12 healthy adults who received placebo or pinacidil 25 mg daily for 1 week in a cross-over experiment. Diastolic blood pressure (DBP) and heart rate (HR) were recorded and blood samples were taken on days 1 and 7. Plasma drug concentration-time data were fitted by a biexponential function with zero-order input. The pharmacokinetic model was incorporated into a combined pharmacokinetic-dynamic model (PK-PD) using the Hill equation, which has three parameters: n, the sigmoidicity parameter, Emax the maximum effect and EC50 the concentration which gives 50% of Emax. For delta DBP, the parameter medians were estimated as n = 5, EC50 = 44.6 ng.ml-1 and Emax = 13.5 mmHg. A hysteresis loop was found when delta HR was plotted against concentration, which could be fitted by a linear effect compartment model. Simulations showed that experimental delta DBP points on Day 7 could be predicted from a simulated curve computed by the model using parameters estimated on Day 1. Using the simulation, it was possible to suggest an optimal dosage regimen for pinacidil tablets.

摘要

在一项交叉试验中,对12名健康成年人进行了外周血管扩张剂吡那地尔的浓度-效应关系测定,这些受试者接受了安慰剂或每日25毫克吡那地尔治疗,为期1周。记录了舒张压(DBP)和心率(HR),并在第1天和第7天采集了血样。血浆药物浓度-时间数据采用零级输入的双指数函数拟合。使用希尔方程将药代动力学模型纳入药代动力学-动力学联合模型(PK-PD),该方程有三个参数:n,S形参数;Emax,最大效应;EC50,产生50%Emax的浓度。对于ΔDBP,参数中位数估计为n = 5,EC50 = 44.6 ng.ml-1,Emax = 13.5 mmHg。当绘制ΔHR与浓度的关系图时发现了一个滞后环,可用线性效应室模型拟合。模拟结果表明,第7天的实验性ΔDBP点可以根据使用第1天估计的参数由模型计算出的模拟曲线进行预测。通过模拟,可以为吡那地尔片剂提出最佳给药方案。

相似文献

1
Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers.匹那地尔对正常血压志愿者血流动力学效应的药效学模型
Eur J Clin Pharmacol. 1993;44(2):177-82. doi: 10.1007/BF00315477.
2
Pharmacodynamics and pharmacokinetics of pinacidil after a single dose of a new slow release tablet in healthy volunteers.单剂量新型缓释片在健康志愿者体内的匹那地尔药效学和药代动力学研究。
Arzneimittelforschung. 1998 Jul;48(7):730-3.
3
Pharmacokinetic-pharmacodynamic modeling between pinacidil or pinacidil-N-oxide plasma levels and systemic and regional hemodynamic effects in healthy volunteers.
Fundam Clin Pharmacol. 1994;8(5):437-45. doi: 10.1111/j.1472-8206.1994.tb00823.x.
4
Acute haemodynamic effects of pinacidil in man.匹那地尔对人体的急性血流动力学效应。
Br J Clin Pharmacol. 1986 Sep;22(3):287-92. doi: 10.1111/j.1365-2125.1986.tb02889.x.
5
Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.
Eur J Clin Pharmacol. 1984;26(5):603-8. doi: 10.1007/BF00543493.
6
Modeling of the pharmacokinetic/pharmacodynamic interaction between irbesartan and hydrochlorothiazide in normotensive subjects.正常血压受试者中厄贝沙坦与氢氯噻嗪药代动力学/药效学相互作用的模型构建
Biopharm Drug Dispos. 2015 May;36(4):216-31. doi: 10.1002/bdd.1935. Epub 2015 Feb 4.
7
Actions of pinacidil at a reduced potassium concentration: a direct cardiac effect possibly involving the ATP-dependent potassium channel.吡那地尔在低钾浓度时的作用:一种可能涉及ATP依赖性钾通道的直接心脏效应。
J Cardiovasc Pharmacol. 1993 Feb;21(2):179-90. doi: 10.1097/00005344-199302000-00001.
8
Acute hemodynamic effects of pinacidil in hypertensive patients with and without propranolol pretreatment.
J Clin Pharmacol. 1991 Apr;31(4):333-41. doi: 10.1002/j.1552-4604.1991.tb03714.x.
9
Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension.
J Clin Pharmacol. 1989 Jan;29(1):33-40. doi: 10.1002/j.1552-4604.1989.tb03234.x.
10
Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.血管紧张素II拮抗剂缬沙坦在健康、血压正常受试者稳态下的药代动力学和药效学效应。
Eur J Clin Pharmacol. 1997;52(6):441-9. doi: 10.1007/s002280050317.

引用本文的文献

1
Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.理解药代动力学/药效动力学关系中的滞后环难题。
J Pharm Pharm Sci. 2014;17(1):34-91.

本文引用的文献

1
HEREDITARY TRANSMISSION OF EXCEPTIONAL RESISTANCE TO COUMARIN ANTICOAGULANT DRUGS. THE FIRST REPORTED KINDRED.遗传性对香豆素抗凝药物的异常抵抗。首例报道的家族系谱。
N Engl J Med. 1964 Oct 15;271:809-15. doi: 10.1056/NEJM196410152711602.
2
Effect of a new vasodilator, pinacidil (P 1134), on potassium, noradrenaline and serotonin induced contractions in rabbit vascular tissues.新型血管扩张剂匹那地尔(P 1134)对兔血管组织中钾、去甲肾上腺素和5-羟色胺诱导收缩的影响。
Acta Pharmacol Toxicol (Copenh). 1981 Nov;49(5):427-31. doi: 10.1111/j.1600-0773.1981.tb00927.x.
3
Metabolism of the new antihypertensive agent pinacidil in rat, dog and man.
Xenobiotica. 1982 Mar;12(3):187-96. doi: 10.3109/00498258209046793.
4
Pharmacokinetics and distribution of the new antihypertensive agent pinacidil in rat, dog and man.新型抗高血压药物匹那地尔在大鼠、犬和人体中的药代动力学及分布
Xenobiotica. 1982 Mar;12(3):177-85. doi: 10.3109/00498258209046792.
5
Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.理解剂量-效应关系:药代动力学-药效学模型的临床应用
Clin Pharmacokinet. 1981 Nov-Dec;6(6):429-53. doi: 10.2165/00003088-198106060-00002.
6
Blood pressure and heart rate variabilities in normotensive and hypertensive human beings.
Circ Res. 1983 Jul;53(1):96-104. doi: 10.1161/01.res.53.1.96.
7
Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension.
Eur J Clin Pharmacol. 1983;25(4):557-61. doi: 10.1007/BF00542128.
8
Pinacidil monotherapy for hypertension.吡那地尔单药治疗高血压。
Br J Clin Pharmacol. 1984 Aug;18(2):223-5. doi: 10.1111/j.1365-2125.1984.tb02456.x.
9
Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.
Eur J Clin Pharmacol. 1984;26(5):603-8. doi: 10.1007/BF00543493.
10
Vascular effects in dogs of pinacidil (P 1134), a novel vasoactive antihypertensive agent.
Eur J Pharmacol. 1983 Apr 8;88(4):389-92. doi: 10.1016/0014-2999(83)90591-5.